Monoclonal antibodies (mAbs) represent a cornerstone of modern therapeutic development, offering unparalleled specificity for targeting specific biological pathways. We provide comprehensive, integrated solutions tailored to the unique complexities of mAb development and large-scale production. Our dedicated facilities and scientific teams empower innovators to navigate the path from discovery to global supply efficiently and reliably. Explore our broader capabilities in CDMO Solutions and Biologic CDMO Solutions.
Comprehensive mAb Development & Manufacturing
The journey of a mAb therapeutic from candidate selection to commercial launch is intricate, demanding specialized expertise at every stage. Challenges include achieving high expression titers, ensuring consistent product quality attributes (especially glycosylation profiles), implementing robust purification strategies to remove host cell impurities and aggregates, and developing stable formulations suitable for patient administration. Our purpose-built mAb CDMO platform is engineered to address these specific challenges. We offer seamless integration across the entire product lifecycle – from cell line development using state-of-the-art platforms, through process development and optimization, clinical and commercial manufacturing, to rigorous analytical development and testing. This integrated approach mitigates technology transfer risks, accelerates timelines, and ensures the highest standards of quality and regulatory compliance are met consistently.
Our Integrated mAb CDMO Services
Our dedicated suite of services is meticulously designed to support the unique requirements of monoclonal antibody programs, ensuring scientific excellence and operational efficiency from concept to patient.
Advanced Cell Line Development & Engineering
We leverage high-throughput platforms and advanced technologies (e.g., targeted integration) to rapidly generate high-producing, stable clonal cell lines. Our focus includes stringent screening for critical quality attributes (CQAs) early in development and optimizing cell lines for manufacturability and scalability.
Specialized Process Development & Optimization
Our scientists develop robust, scalable upstream processes using advanced fed-batch or perfusion strategies to maximize mAb titer and quality. Downstream purification processes are tailored to the specific characteristics of each mAb, employing platform approaches refined by molecule-specific optimization. This includes dedicated strategies for effective removal of host cell proteins, DNA, viruses, aggregates, and fragments, alongside precise control of charge variants and glycan profiles.
Analytical Method Development & Characterization
Comprehensive characterization is paramount. We develop, qualify, and validate a full spectrum of analytical methods, including potency assays (binding and functional), purity and impurity profiling (SEC-HPLC, CE-SDS, iCIEF), structural analysis (Mass spectrometry for sequence, glycosylation, modifications), and stability-indicating methods. Extended characterization studies provide deep insights into product attributes.
Formulation, Fill-Finish & Stability
Developing stable, high-concentration formulations suitable for subcutaneous or intravenous delivery is a core competency. Our aseptic fill-finish capabilities encompass vial, syringe, and cartridge formats using state-of-the-art isolator technology. We design and execute comprehensive stability studies (real-time, accelerated, stress) under ICH guidelines to define shelf-life and storage conditions.
cGMP Manufacturing
We operate dedicated, flexible cGMP manufacturing (small-batch GMP production and clinical manufacturing) suites designed specifically for monoclonal antibodies. Each batch undergoes rigorous quality control testing, ensuring compliance with regulatory requirements. We also offer process monitoring and documentation, providing full traceability and reproducibility from pilot to large-scale commercial batches.
We offer a complete, scientifically driven pathway for monoclonal antibody development and manufacturing. Partnering with us provides access to deep technical expertise, integrated services, and scalable cGMP capacity, significantly de-risking your program and accelerating time to market. Contact us today to discuss how we can advance your monoclonal antibody therapeutic.
Frequently Asked Questions
Q1: How does your platform approach benefit novel or complex mAb formats (e.g., bispecifics, Fc-engineered)?
While utilizing platform processes for efficiency, our approach is fundamentally molecule-specific. For novel formats like bispecific antibodies or Fc-engineered molecules, we conduct tailored development. This includes customized cell line engineering to ensure correct chain pairing and assembly, bespoke purification strategies to separate mispaired species or achieve desired purity levels, and specialized analytical methods to characterize unique structural features and functionalities.
Q2: What strategies do you employ to ensure optimal glycosylation profiles critical for mAb efficacy and safety?
Glycosylation control is a critical focus. We employ a multi-faceted strategy: selecting cell lines with desirable glycosylation potential, optimizing upstream process parameters to steer glycan profiles, implementing purification steps that do not adversely impact glycans, and developing highly sensitive analytical methods (HILIC-UPLC, MS) for detailed glycan mapping and monitoring.
Our products and services are for research use only.
